BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34799346)

  • 1. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
    Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
    Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
    Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C
    Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
    Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
    Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
    Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
    Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
    Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
    Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
    Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
    Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
    Front Immunol; 2020; 11():89. PubMed ID: 32184777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
    Guo L; Liu Z; Zhang Y; Quan Q; Huang L; Xu Y; Cao L; Zhang X
    Medicine (Baltimore); 2019 Feb; 98(8):e14663. PubMed ID: 30813210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
    Lecker LSM; Berlato C; Maniati E; Delaine-Smith R; Pearce OMT; Heath O; Nichols SJ; Trevisan C; Novak M; McDermott J; Brenton JD; Cutillas PR; Rajeeve V; Hennino A; Drapkin R; Loessner D; Balkwill FR
    Cancer Res; 2021 Nov; 81(22):5706-5719. PubMed ID: 34561272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 immunoregulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Deng M; Wu D; Zhang Y; Jin Z; Miao J
    Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.